IMGN News and Press, ImmunoGen Inc. From 12/09/19

Data Demonstrating Potential in AML and BPDCN Presented During Oral Presentation; Dose and Schedule Selected for Further Development Preclinical Combination Data Also Presented; Support Further Evaluation of IMGN632 Doublets and Triplet in AML ImmunoGen, Inc. , (Nasdaq: IMGN) a l...

These 5 Penny Stocks Are Presenting Key Data This Week; Are They A Good Buy Or a Goodbye For Investors? No matter your feeling on penny stocks , one glaring fact remains. You can make quick money with these cheap stocks. The idea that someone can buy penny stocks in sizes of 100,000 shares o...

3 Penny Stocks To Watch In December Penny stocks are unique in the aspect that they don’t always adhere to the overall market trends. This week, most of the blue-chip stocks you hear about on CNBC or Fox saw little change since the beginning of the week. Most analysts are monitoring...

Shares of ImmunoGen (NASDAQ: IMGN) closed Wednesday 12.4% higher as investors piled into the biotech ahead of the American Society of Hematology (ASH) Annual Meeting, which starts Saturday. http://investor.immunogen.com/news-releases/news-release-details/immunogen-present-new-data-imgn632-...

Introduction This forensic value analysis began with a check of four different algorithm scores of Tesla, Inc. ( TSLA ) at the request of members of my service back in October 2018. The question they asked at the time was, "what risk does Tesla, Inc. pose as an investment?" In an ad hoc quer...

ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will participate in a fireside chat at the upcoming Piper Jaffray Healthcare Conference. The fireside chat is scheduled for 12:30...

The largest profits in the investment field go to those who are capable of correctly zigging when the financial community is zagging. - Phillip Fisher In bioscience investing, a turnaround stock is certainly not for everyone. For a turnaround company, the lucrative profits arrive at th...

Updated Phase 1 Data to be Highlighted in Oral Presentation Demonstrate Tolerable Safety Profile and Encouraging Activity in AML and BPDCN Preclinical Data for IMGN632 in Combination with Azacitidine and Venetoclax Support Clinical Evaluation of Doublets and Triplet in AML Immuno...

Shares of ImmunoGen (NASDAQ: IMGN) were soaring 14.8% higher as of 11:20 a.m. EST on Tuesday. The biotech provided its third-quarter update last Friday. While its financial results were nothing to get excited about, investors cheered its progress with a late-stage clinical study evaluating...

ImmunoGen Inc (IMGN) Q3 2019 Results Earnings Conference Call November 1, 2019 8:00 AM ET Company Participants Courtney O'Konek - Senior Director of Corporate Communications and Investor Relations Mark Enyedy - President and Chief Executive Officer Anna Berkenblit - Senior Vice...